# Filing Detail

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001129928-23-000013
Filing Date
2023-04-06
Accepted
2023-04-06 11:24:15
Documents
8
Period of Report
2022-12-31

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 6-K | a2023informationcircularfo.htm | 6-K | 20237
2 | EX-99.1 | onc-2023circularfinal.htm | EX-99.1 | 499442
3 | EX-99.2 | oncolytics-proxy2023fina.htm | EX-99.2 | 11027
4 |  | image_0a.jpg | GRAPHIC | 74787
5 |  | image_1a.jpg | GRAPHIC | 15395
6 |  | image_4a.jpg | GRAPHIC | 107818
7 |  | oncolytics-proxy2023fina001.jpg | GRAPHIC | 206169
8 |  | oncolytics-proxy2023fina002.jpg | GRAPHIC | 215422
| Complete submission text file | 0001129928-23-000013.txt |  | 1384702

Mailing Address 804, 322 - 11 AVENUE SW CALGARY A0 T2R 0C5
Business Address 804, 322 - 11 AVENUE SW CALGARY A0 T2R 0C5 4036707380
ONCOLYTICS BIOTECH INC (Filer) CIK: 0001129928 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-38512 | Film No.: 23804958
SIC: 2834 Pharmaceutical Preparations